RemeGen Raises $515 Million in Hong Kong IPO, Company Valued at $4.3 Billion

RemeGen, a Yantai biotech approaching commercial stage, completed a $515 million IPO on the Hong Kong exchange in the largest biotech IPO of the year. Founded in 2008, RemeGen is developing a portfolio of ten novel mAbs, fusion proteins, antibody-drug conjugates (ADCs) and bifunctional antibodies. Two of its candidates are under NDA review in China : telitacicept for autoimmune diseases (systemic lupus erythematosus) and disitamab vedotin for HER2 cancers. The company's shares have traded 34% higher since the IPO, giving RemeGen a market capitalization of $4.3 billion. More details.... Stock Symbol: (HK: 9995) Share this with colleagues: // //